Navigation Links
Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
Date:1/6/2011

SEATTLE, Jan. 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Friday, January 7, 2011 at 9:00 a.m. ET to provide updates on U.S. commercialization progress, European strategy for PROVENGE, and pipeline progress.Date:

Friday, January 7, 2011Time:

9:00 a.m. ET / 6:00 a.m. PTDial-in:

1-877-548-9590 (domestic) or +1-720-545-0037 (international);conference pass code 35063654Webcast:

www.dendreon.com (homepage and investor relations section)A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-642-1687 or +1-706-645-9291 for international callers; the conference ID number is 35063654. The replay will be available from 12:00 p.m. ET on Friday, January 7 until 11:59 p.m. ET on Monday, January 10.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
2. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
3. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
4. Dendreon Announces Change in Board of Directors
5. Dendreon Announces Election of Dr. David C. Stump to Board of Directors
6. Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
7. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
8. Dendreon Announces Pricing of Common Stock Offering
9. Dendreon Appoints Hans Bishop as Chief Operating Officer
10. Dendreon Announces Proposed Public Offering of Common Stock
11. Dendreon Receives FDA Acknowledgement of Complete Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... VILLAGE, Calif. , March 24, 2017   ... dermatology and aesthetics company, today announced that Richard ... Officer, effective March 24.   Peterson, who brings ... succeed John Smither , who is retiring at ... Sienna in an advisory capacity. Peterson joins Sienna from ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ... strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
Breaking Biology News(10 mins):